San Francisco, CA (November 21, 2014): Jaguar Animal Health, Inc. ("Jaguar" or the "Company"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has appointed Tim Dotson, a veteran animal health executive with more than 20 years of industry experience, as Executive Director, Regulatory Affairs.
Prior to joining Jaguar, Mr. Dotson was Director of Regulatory Affairs for Merial Limited, a global animal health subsidiary of Sanofi S.A., from 2002 to 2014, where he managed FDA projects and achieved multiple FDA approvals for new drugs for dogs, cats and horses, including approval for NexGard™ Chewables, a first-in-class drug indicated for the treatment and control of fleas and ticks in dogs. From 2009 to 2010, Mr. Dotson served as Chair of the Animal Drug Section (ADS) of the Animal Health Institute, as well as a Steering Committee delegate of the ADS Leadership Team. Mr. Dotson holds a Master of Science degree in Toxicology from the American University in Washington, DC, as well as a Bachelor of Science degree in Biology from Virginia Polytechnic Institute and State University in Blacksburg, VA.
"We are thrilled to have Tim join Jaguar's team," stated Jaguar CEO Lisa Conte. "We expect that his experience and track record of success will prove invaluable as we pursue marketing approval for the eight investigational new animal drugs for which we have applications on file with the FDA, and as we initiate our first filing, by the end of 2014, of a rolling new animal drug application, or NADA, for Canalevia™ for chemotherapy-induced diarrhea, or CID, in dogs."
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Canalevia is Jaguar's lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. Neonorm™ Calf is the company's lead non-prescription product. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Neonorm is a botanical extract derived from the Croton lechleri tree. Canalevia and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has filed eight investigational new animal drug applications, or INADs, with the FDA and intends to develop species-specific formulations of Neonorm in six additional target species.
For more information, please visit www.jaguaranimalhealth.com.